Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer

Mark Daniel, Scott M. Dehm

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Androgen receptor (AR) splice variants (AR-Vs) are constitutively active transcription factors that function in the absence of ligand. AR-Vs represent one of several AR re-activation mechanisms utilized by prostate cancer to circumvent first-line androgen deprivation therapy. Second line therapies such as enzalutamide and abiraterone are treatments that re-target components of the androgen/AR axis. However, these second line therapies do not benefit all patients, and patients that do receive initial benefit can develop resistance rapidly. Alterations in components of the androgen/AR axis, including expression of AR-Vs, appear to be linked to primary as well as secondary resistance to second line therapies. However, some key conclusions appear to differ depending on the tissue compartment and measurement platform utilized for analysis. In this review, alterations in AR and the broader AR pathway will be examined in the context of primary prostate cancer tissue, metastatic castration-resistant prostate cancer tissue, circulating tumor cells, and circulating cell-free tumor DNA. Questions regarding the utility of AR-V measurements to provide prognostic information or predict patient responses to AR-targeted therapies will be addressed.

Original languageEnglish (US)
Pages (from-to)28-37
Number of pages10
JournalJournal of Steroid Biochemistry and Molecular Biology
StatePublished - Feb 1 2017

Bibliographical note

Publisher Copyright:
© 2016 Elsevier Ltd


  • Androgen receptor splice variant
  • Castration-resistant prostate cancer
  • Circulating tumor cell
  • Prostate cancer


Dive into the research topics of 'Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer'. Together they form a unique fingerprint.

Cite this